This issue of JAMA Neurology includes a methodologically rigorous systematic review and meta-analysis examining the efficacy of benzodiazepines and antihistamines in patients with acute vertigo. 1 Hunter and colleagues 1 chose an important, common clinical problem, systematically searched for relevant evidence, and then assessed the studies for both quality and risk of bias. Their primary outcome was symptom control of vertigo at 2 hours measured by a visual analog score. Secondary outcomes included symptom control at later time points. Symptom control is clearly an important patient-centric outcome; therefore, their study is relevant and timely.Hunter and colleagues 1 found that antihistamines were superior to benzodiazepines at 2 hours but not at 1 week or 1 month. Importantly, as the authors themselves acknowledge, we do not know if the statistically significant difference in self-rated symptom severity is clinically meaningful. Of the 16 studies analyzed, 9 of them gave the vestibular suppressant for "1 week to 2 months." 1 This duration of medication was in the setting of clinical trials; however, in real-life practice, patients often continue treatment with vestibular suppressants for far longer periods of time. 2,3 Of course, correct treatment of acute vertigo depends on first making a correct diagnosis-something that cannot necessarily be taken for granted. It is worth noting that Hunter et al 1 included studies of patients with acute vertigo of any cause. However, comparing symptomatic treatments for patients with acute vertigo without first determining a specific central or peripheral vestibular diagnosis ignores an enormous body of clinically relevant literature that supports disease-specific treatment. Imagine 3 emergency department (ED) patients with isolated acute vertigo or dizziness. One has typical benign paroxysmal positional vertigo (BPPV), one has vestibular neuritis, and the third has an ischemic cerebellar stroke. The study by Hunter et al 1 shows that antihistamines are more effective than benzodiazepines at controlling acute symptoms, but that is only 1 component of best management. Clearly, the ideal strategy would be to begin with a correct diagnosis, then treat accordingly in disease-specific fashion: (1) canalith repositioning maneuver for BPPV, (2) corticosteroids plus short-term (ie, 3-5 days) vestibular suppressants (Hunter and colleagues 1 would say antihistamines) and early vestibular rehabilitation for vestibular neuritis, and (3) dual antiplatelet therapy as emergent secondary prevention (or other appropriate acute stroke treatment) for the patient with posterior circulation ischemia.